|Alcoholic hepatitis as seen with a microscope, showing fatty changes (white circles), remnants of dead liver cells, and Mallory bodies (twisted-rope shaped inclusions within some liver cells). (H&E stain)|
|Specialty||Infectious disease, gastroenterology, hepatology|
|Symptoms||Yellowish skin, poor appetite, abdominal pain|
|Complications||Scarring of the liver, liver failure, liver cancer|
|Duration||Short term or long term|
|Causes||Viruses, alcohol, toxins, autoimmune|
|Prevention||Vaccination (for viral hepatitis), avoiding excessive alcohol|
|Treatment||Medication, liver transplant|
|Frequency||> 500 million cases|
|Deaths||> One million a year|
Hepatitis is inflammation of the liver tissue. Some people with hepatitis have no symptoms, whereas others develop yellow discoloration of the skin and whites of the eyes (jaundice), poor appetite, vomiting, tiredness, abdominal pain, and diarrhea. Hepatitis is acute if it resolves within six months, and chronic if it lasts longer than six months. Acute hepatitis can resolve on its own, progress to chronic hepatitis, or (rarely) result in acute liver failure. Chronic hepatitis may progress to scarring of the liver (cirrhosis), liver failure, and liver cancer.
Hepatitis is most commonly caused by the viruses hepatitis A, B, C, D, and E. Other causes include heavy alcohol use, certain medications, toxins, other infections, autoimmune diseases, and non-alcoholic steatohepatitis (NASH). Hepatitis A and E are mainly spread by contaminated food and water. Hepatitis B is mainly sexually transmitted, but may also be passed from mother to baby during pregnancy or childbirth and spread through infected blood. Hepatitis C is commonly spread through infected blood such as may occur during needle sharing by intravenous drug users. Hepatitis D can only infect people already infected with hepatitis B.
Hepatitis A, B, and D are preventable with immunization. Medications may be used to treat chronic viral hepatitis. Antiviral medications are recommended in all with chronic hepatitis C, except those with conditions that limit their life expectancy. There is no specific treatment for NASH; however, physical activity, a healthy diet, and weight loss are recommended. Autoimmune hepatitis may be treated with medications to suppress the immune system. A liver transplant may be an option in both acute and chronic liver failure.
Worldwide in 2015, hepatitis A occurred in about 114 million people, chronic hepatitis B affected about 343 million people and chronic hepatitis C about 142 million people. In the United States, NASH affects about 11 million people and alcoholic hepatitis affects about 5 million people. Hepatitis results in more than a million deaths a year, most of which occur indirectly from liver scarring or liver cancer. In the United States, hepatitis A is estimated to occur in about 2,500 people a year and results in about 75 deaths. The word is derived from the Greek hêpar (ἧπαρ), meaning "liver", and -itis (-ῖτις), meaning "inflammation".
Signs and symptoms
Hepatitis has a broad spectrum of presentations that range from a complete lack of symptoms to severe liver failure. The acute form of hepatitis, generally caused by viral infection, is characterized by constitutional symptoms that are typically self-limiting. Chronic hepatitis presents similarly, but can manifest signs and symptoms specific to liver dysfunction with long-standing inflammation and damage to the organ.
Acute viral hepatitis follows three distinct phases:
- The initial prodromal phase (preceding symptoms) involves non-specific and flu-like symptoms common to many acute viral infections. These include fatigue, nausea, vomiting, poor appetite, joint pain, and headaches. Fever, when present, is most common in cases of hepatitis A and E. Late in this phase, people can experience liver-specific symptoms, including choluria (dark urine) and clay-colored stools.
- Yellowing of the skin and whites of the eyes follow the prodrome after about 1–2 weeks and can last for up to 4 weeks. The non-specific symptoms seen in the prodromal typically resolve by this time, but people will develop an enlarged liver and right upper abdominal pain or discomfort. 10–20% of people will also experience an enlarged spleen, while some people will also experience a mild unintentional weight loss.
- The recovery phase is characterized by resolution of the clinical symptoms of hepatitis with persistent elevations in liver lab values and potentially a persistently enlarged liver. All cases of hepatitis A and E are expected to fully resolve after 1–2 months. Most hepatitis B cases are also self-limiting and will resolve in 3–4 months. Few cases of hepatitis C will resolve completely.
Both drug-induced hepatitis and autoimmune hepatitis can present very similarly to acute viral hepatitis, with slight variations in symptoms depending on the cause. Cases of drug-induced hepatitis can manifest with systemic signs of an allergic reaction including rash, fever, serositis (inflammation of membranes lining certain organs), elevated eosinophils (a type of white blood cell), and suppression of bone marrow activity.
Fulminant hepatitis, or massive hepatic cell death, is a rare and life-threatening complication of acute hepatitis that can occur in cases of hepatitis B, D, and E, in addition to drug-induced and autoimmune hepatitis. The complication more frequently occurs in instances of hepatitis B and D co-infection at a rate of 2–20% and in pregnant women with hepatitis E at rate of 15–20% of cases. In addition to the signs of acute hepatitis, people can also demonstrate signs of coagulopathy (abnormal coagulation studies with easy bruising and bleeding) and encephalopathy (confusion, disorientation, and sleepiness). Mortality due to fulminant hepatitis is typically the result of various complications including cerebral edema, gastrointestinal bleeding, sepsis, respiratory failure, or kidney failure.
Acute cases of hepatitis are seen to be resolved well within a six-month period. When hepatitis is continued for more than six months it is termed chronic hepatitis. Chronic hepatitis is often asymptomatic early in its course and is detected only by liver laboratory studies for screening purposes or to evaluate non-specific symptoms. As the inflammation progresses, patients can develop constitutional symptoms similar to acute hepatitis, including fatigue, nausea, vomiting, poor appetite, and joint pain. Jaundice can occur as well, but much later in the disease process and is typically a sign of advanced disease. Chronic hepatitis interferes with hormonal functions of the liver which can result in acne, hirsutism (abnormal hair growth), and amenorrhea (lack of menstrual period) in women. Extensive damage and scarring of the liver over time defines cirrhosis, a condition in which the liver's ability to function is permanently impeded. This results in jaundice, weight loss, coagulopathy, ascites (abdominal fluid collection), and peripheral edema (leg swelling). Cirrhosis can lead to other life-threatening complications such as hepatic encephalopathy, esophageal varices, hepatorenal syndrome, and liver cancer.
Causes of hepatitis can be divided into the following major categories: infectious, metabolic, ischemic, autoimmune, genetic, and other. Infectious agents include viruses, bacteria, and parasites. Metabolic causes include prescription medications, toxins (most notably alcohol), and non-alcoholic fatty liver disease. Autoimmune and genetic causes of hepatitis involve genetic predispositions and tend to affect characteristic populations.
Viral hepatitis is the most common type of hepatitis worldwide. Viral hepatitis is caused by five different viruses (hepatitis A, B, C, D, and E). Hepatitis A and hepatitis E behave similarly: they are both transmitted by the fecal–oral route, are more common in developing countries, and are self-limiting illnesses that do not lead to chronic hepatitis.
Hepatitis B, hepatitis C, and hepatitis D are transmitted when blood or mucous membranes are exposed to infected blood and body fluids, such as semen and vaginal secretions. Viral particles have also been found in saliva and breastmilk. However, kissing, sharing utensils, and breastfeeding do not lead to transmission unless these fluids are introduced into open sores or cuts.
Hepatitis B and C can present either acutely or chronically. Hepatitis D is a defective virus that requires hepatitis B to replicate and is only found with hepatitis B co-infection. In adults, hepatitis B infection is most commonly self-limiting, with less than 5% progressing to chronic state, and 20 to 30% of those chronically infected developing cirrhosis or liver cancer. However, infection in infants and children frequently leads to chronic infection.
Unlike hepatitis B, most cases of hepatitis C lead to chronic infection. Hepatitis C is the second most common cause of cirrhosis in the US (second to alcoholic hepatitis). In the 1970s and 1980s, blood transfusions were a major factor in spreading hepatitis C virus. Since widespread screening of blood products for hepatitis C began in 1992, the risk of acquiring hepatitis C from a blood transfusion has decreased from approximately 10% in the 1970s to 1 in 2 million currently.
Parasites can also infect the liver and activate the immune response, resulting in symptoms of acute hepatitis with increased serum IgE (though chronic hepatitis is possible with chronic infections). Of the protozoans, Trypanosoma cruzi, Leishmania species, and the malaria-causing Plasmodium species all can cause liver inflammation. Another protozoan, Entamoeba histolytica, causes hepatitis with distinct liver abscesses.
Of the worms, the cestode Echinococcus granulosus, also known as the dog tapeworm, infects the liver and forms characteristic hepatic hydatid cysts. The liver flukes Fasciola hepatica and Clonorchis sinensis live in the bile ducts and cause progressive hepatitis and liver fibrosis.
Bacterial infection of the liver commonly results in pyogenic liver abscesses, acute hepatitis, or granulomatous (or chronic) liver disease. Pyogenic abscesses commonly involve enteric bacteria such as Escherichia coli and Klebsiella pneumoniae and are composed of multiple bacteria up to 50% of the time. Acute hepatitis is caused by Neisseria meningitidis, Neisseria gonorrhoeae, Bartonella henselae, Borrelia burgdorferi, salmonella species, brucella species and campylobacter species. Chronic or granulomatous hepatitis is seen with infection from mycobacteria species, Tropheryma whipplei, Treponema pallidum, Coxiella burnetii, and rickettsia species.
Excessive alcohol consumption is a significant cause of hepatitis and is the most common cause of cirrhosis in the U.S. Alcoholic hepatitis is within the spectrum of alcoholic liver disease. This ranges in order of severity and reversibility from alcoholic steatosis (least severe, most reversible), alcoholic hepatitis, cirrhosis, and liver cancer (most severe, least reversible). Hepatitis usually develops over years-long exposure to alcohol, occurring in 10 to 20% of alcoholics. The most important risk factors for the development of alcoholic hepatitis are quantity and duration of alcohol intake. Long-term alcohol intake in excess of 80 grams of alcohol a day in men and 40 grams a day in women is associated with development of alcoholic hepatitis (1 beer or 4 ounces of wine is equivalent to 12g of alcohol). Alcoholic hepatitis can vary from asymptomatic hepatomegaly (enlarged liver) to symptoms of acute or chronic hepatitis to liver failure.
Toxic and drug-induced hepatitis
Many chemical agents, including medications, industrial toxins, and herbal and dietary supplements, can cause hepatitis. The spectrum of drug-induced liver injury varies from acute hepatitis to chronic hepatitis to acute liver failure. Toxins and medications can cause liver injury through a variety of mechanisms, including direct cell damage, disruption of cell metabolism, and causing structural changes. Some drugs such as paracetamol exhibit predictable dose-dependent liver damage while others such as isoniazid cause idiosyncratic and unpredictable reactions that vary among individuals. There are wide variations in the mechanisms of liver injury and latency period from exposure to development of clinical illness.
Many types of drugs can cause liver injury, including the analgesic paracetamol; antibiotics such as isoniazid, nitrofurantoin, amoxicillin-clavulanate, erythromycin, and trimethoprim-sulfamethoxazole; anticonvulsants such as valproate and phenytoin; cholesterol-lowering statins; steroids such as oral contraceptives and anabolic steroids; and highly active anti-retroviral therapy used in the treatment of HIV/AIDS. Of these, amoxicillin-clavulanate is the most common cause of drug-induced liver injury, and paracetamol toxicity the most common cause of acute liver failure in the United States and Europe.
Herbal remedies and dietary supplements are another important cause of hepatitis; these are the most common causes of drug-induced hepatitis in Korea. The United-States-based Drug Induced Liver Injury Network linked more than 16% of cases of hepatotoxicity to herbal and dietary supplements. In the United States, herbal and dietary supplements – unlike pharmaceutical drugs – are unregulated by the Food and Drug Administration. However, the National Institutes of Health maintains the LiverTox database for consumers to track all known prescription and non-prescription compounds associated with liver injury.
Exposure to other hepatotoxins can occur accidentally or intentionally through ingestion, inhalation, and skin absorption. The industrial toxin carbon tetrachloride and the wild mushroom Amanita phalloides are other known hepatotoxins.
Non-alcoholic fatty liver disease
Non-alcoholic hepatitis is within the spectrum of non-alcoholic liver disease (NALD), which ranges in severity and reversibility from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH) to cirrhosis to liver cancer, similar to the spectrum of alcoholic liver disease.
Non-alcoholic liver disease occurs in people with little or no history of alcohol use, and is instead strongly associated with metabolic syndrome, obesity, insulin resistance and diabetes, and hypertriglyceridemia. Over time, non-alcoholic fatty liver disease can progress to non-alcoholic steatohepatitis, which additionally involves liver cell death, liver inflammation and possible fibrosis. Factors accelerating progression from NAFLD to NASH are obesity, older age, non-African American ethnicity, female gender, diabetes mellitus, hypertension, higher ALT or AST level, higher AST/ALT ratio, low platelet count, and an ultrasound steatosis score.
In the early stages (as with NAFLD and early NASH), most patients are asymptomatic or have mild right upper quadrant pain, and diagnosis is suspected on the basis of abnormal liver function tests. As the disease progresses, symptoms typical of chronic hepatitis may develop. While imaging can show fatty liver, only liver biopsy can demonstrate inflammation and fibrosis characteristic of NASH. 9 to 25% of patients with NASH develop cirrhosis. NASH is recognized as the third most common cause of liver disease in the United States.
Autoimmune hepatitis is a chronic disease caused by an abnormal immune response against liver cells. The disease is thought to have a genetic predisposition as it is associated with certain human leukocyte antigens involved in the immune response. As in other autoimmune diseases, circulating auto-antibodies may be present and are helpful in diagnosis. Auto-antibodies found in patients with autoimmune hepatitis include the sensitive but less specific anti-nuclear antibody (ANA), smooth muscle antibody (SMA), and atypical perinuclear antineutrophil cytoplasmic antibody (p-ANCA). Other autoantibodies that are less common but more specific to autoimmune hepatitis are the antibodies against liver kidney microsome 1 (LKM1) and soluble liver antigen (SLA). Autoimmune hepatitis can also be triggered by drugs (such as nitrofurantoin, hydralazine, and methyldopa), after liver transplant, or by viruses (such as hepatitis A, Epstein-Barr virus, or measles).
Autoimmune hepatitis can present anywhere within the spectrum from asymptomatic to acute or chronic hepatitis to fulminant liver failure. Patients are asymptomatic 25–34% of the time, and the diagnosis is suspected on the basis of abnormal liver function tests. Up to 40% of cases present with signs and symptoms of acute hepatitis. As with other autoimmune diseases, autoimmune hepatitis usually affects young women (though it can affect patients of either sex of any age), and patients can exhibit classic signs and symptoms of autoimmunity such as fatigue, anemia, anorexia, amenorrhea, acne, arthritis, pleurisy, thyroiditis, ulcerative colitis, nephritis, and maculopapular rash. Autoimmune hepatitis increases the risk for cirrhosis, and the risk for liver cancer is increased by about 1% for each year of the disease.
Many people with autoimmune hepatitis have other autoimmune diseases. Autoimmune hepatitis is distinct from the other autoimmune diseases of the liver: primary biliary cirrhosis and primary sclerosing cholangitis. However, all of these diseases can lead to scarring, fibrosis, and cirrhosis of the liver.
Genetic causes of hepatitis include alpha-1-antitrypsin deficiency, hemochromatosis, and Wilson's disease. In alpha-1-antitrypsin deficiency, a co-dominant mutation in the gene for alpha-1-antitrypsin results in the abnormal accumulation of the mutant AAT protein within liver cells, leading to liver disease. Hemochromatosis and Wilson's disease are both autosomal recessive diseases involving abnormal storage of minerals. In hemochromatosis, excess amounts of iron accumulate in multiple body sites, including the liver, which can lead to cirrhosis. In Wilson's disease, excess amounts of copper accumulate in the liver and brain, causing cirrhosis and dementia.
When the liver is involved, alpha-1-antitrypsin deficiency and Wilson's disease tend to present as hepatitis in the neonatal period or in childhood. Hemochromatosis typically presents in adulthood, with the onset of clinical disease usually after age 50.
Ischemic hepatitis (also known as shock liver) results from reduced blood flow to the liver as in shock, heart failure, or vascular insufficiency. The condition is most often associated with heart failure but can also be caused by shock or sepsis. Blood testing of a person with ischemic hepatitis will show very high levels of transaminase enzymes (AST and ALT). The condition usually resolves if the underlying cause is treated successfully. Ischemic hepatitis rarely causes permanent liver damage.
Hepatitis can also occur in neonates and is attributable to a variety of causes, some of which are not typically seen in adults. Congenital or perinatal infection with the hepatitis viruses, toxoplasma, rubella, cytomegalovirus, and syphilis can cause neonatal hepatitis. Structural abnormalities such as biliary atresia and choledochal cysts can lead to cholestatic liver injury leading to neonatal hepatitis. Metabolic diseases such as glycogen storage disorders and lysosomal storage disorders are also implicated. Neonatal hepatitis can be idiopathic, and in such cases, biopsy often shows large multinucleated cells in the liver tissue. This disease is termed giant cell hepatitis and may be associated with viral infection, autoimmune disorders, and drug toxicity.
The specific mechanism varies and depends on the underlying cause of the hepatitis. Generally, there is an initial insult that causes liver injury and activation of an inflammatory response, which can become chronic, leading to progressive fibrosis and cirrhosis.
The pathway by which hepatic viruses cause viral hepatitis is best understood in the case of hepatitis B and C. The viruses do not directly cause apoptosis (cell death). Rather, infection of liver cells activates the innate and adaptive arms of the immune system leading to an inflammatory response which causes cellular damage and death. Depending on the strength of the immune response, the types of immune cells involved and the ability of the virus to evade the body's defense, infection can either lead to clearance (acute disease) or persistence (chronic disease) of the virus. The chronic presence of the virus within liver cells results in multiple waves of inflammation, injury and wound healing that over time lead to scarring or fibrosis and culminate in hepatocellular carcinoma. Individuals with an impaired immune response are at greater risk of developing chronic infection. Natural killer cells are the primary drivers of the initial innate response and create a cytokine environment that results in the recruitment of CD4 T-helper and CD8 cytotoxic T-cells. Type I interferons are the cytokines that drive the antiviral response. In chronic Hepatitis B and C, natural killer cell function is impaired.
Steatohepatitis is seen in both alcoholic and non-alcoholic liver disease and is the culmination of a cascade of events that began with injury. In the case of non-alcoholic steatohepatitis, this cascade is initiated by changes in metabolism associated with obesity, insulin resistance, and lipid dysregulation. In alcoholic hepatitis, chronic excess alcohol use is the culprit. Though the inciting event may differ, the progression of events is similar and begins with accumulation of free fatty acids (FFA) and their breakdown products in the liver cells in a process called steatosis. This initially reversible process overwhelms the hepatocyte's ability to maintain lipid homeostasis leading to a toxic effect as fat molecules accumulate and are broken down in the setting of an oxidative stress response. Over time, this abnormal lipid deposition triggers the immune system via toll-like receptor 4 (TLR4) resulting in the production of inflammatory cytokines such as TNF that cause liver cell injury and death. These events mark the transition to steatohepatitis and in the setting of chronic injury, fibrosis eventually develops setting up events that lead to cirrhosis and hepatocellular carcinoma. Microscopically, changes that can be seen include steatosis with large and swollen hepatocytes (ballooning), evidence of cellular injury and cell death (apoptosis, necrosis), evidence of inflammation in particular in zone 3 of the liver, variable degrees of fibrosis and Mallory bodies.
|Most elevated aminotransferase||Cause|
|ALT||Chronic hepatitis B, C, and D|
|Nonalcoholic liver disease|
|Acute viral hepatitis|
|Ischemic hepatitis (severe elevation up to thousands)|
|AST||Alcoholic liver disease|
Diagnosis of hepatitis is made on the basis of some or all of the following: a person's signs and symptoms, medical history including sexual and substance use history, blood tests, imaging, and liver biopsy. In general, for viral hepatitis and other acute causes of hepatitis, the person's blood tests and clinical picture are sufficient for diagnosis. For other causes of hepatitis, especially chronic causes, blood tests may not be useful. In this case, liver biopsy is the gold standard for establishing the diagnosis: histopathologic analysis is able to reveal the precise extent and pattern of inflammation and fibrosis. However, liver biopsy is typically not the initial diagnostic test because it is invasive and is associated with a small but significant risk of bleeding that is increased in people with liver injury and cirrhosis.
Blood testing includes liver enzymes, serology (i.e. for autoantibodies), nucleic acid testing (i.e. for hepatitis virus DNA/RNA), blood chemistry, and complete blood count. Characteristic patterns of liver enzyme abnormalities can point to certain causes or stages of hepatitis. Generally, AST and ALT are elevated in most cases of hepatitis regardless of whether the person shows any symptoms. However, the degree of elevation (i.e. levels in the hundreds vs. in the thousands), the predominance for AST vs. ALT elevation, and the ratio between AST and ALT are informative of the diagnosis.
Ultrasound, CT, and MRI can all identify steatosis (fatty changes) of the liver tissue and nodularity of the liver surface suggestive of cirrhosis. CT and especially MRI are able to provide a higher level of detail, allowing visualization and characterize such structures as vessels and tumors within the liver. Unlike steatosis and cirrhosis, no imaging test is able to detect liver inflammation (i.e. hepatitis) or fibrosis. Liver biopsy is the only definitive diagnostic test that is able to assess inflammation and fibrosis of the liver.
Viral hepatitis is primarily diagnosed through blood tests for levels of viral antigens (such as the hepatitis B surface or core antigen), anti-viral antibodies (such as the anti-hepatitis B surface antibody or anti-hepatitis A antibody), or viral DNA/RNA. In early infection (i.e. within 1 week), IgM antibodies are found in the blood. In late infection and after recovery, IgG antibodies are present and remain in the body for up to years. Therefore, when a patient is positive for IgG antibody but negative for IgM antibody, he is considered immune from the virus via either prior infection and recovery or prior vaccination.
In the case of hepatitis B, blood tests exist for multiple virus antigens (which are different components of the virion particle) and antibodies. The combination of antigen and antibody positivity can provide information about the stage of infection (acute or chronic), the degree of viral replication, and the infectivity of the virus.
Alcoholic versus non-alcoholic
The most apparent distinguishing factor between alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH) is a history of alcohol use or abuse. Thus, in patients who have no or negligible alcohol use, the diagnosis is unlikely to be alcoholic hepatitis. However, in those who use alcohol, the diagnosis may just as likely be alcoholic or nonalcoholic hepatitis especially if there is concurrent obesity, diabetes, and metabolic syndrome. In this case, alcoholic and nonalcoholic hepatitis can be distinguished by the pattern of liver enzyme abnormalities; specifically, in alcoholic steatohepatitis AST>ALT with ratio of AST:ALT>2:1 while in nonalcoholic steatohepatitis ALT>AST with ratio of ALT:AST>1.5:1.
Of note, liver biopsy shows identical findings in patients with ASH and NASH, specifically, the presence of polymorphonuclear infiltration, hepatocyte necrosis and apoptosis in the form of ballooning degeneration, Mallory bodies, and fibrosis around veins and sinuses.
The purpose of screening for viral hepatitis is to identify people infected with the disease as early as possible, even before symptoms and transaminase elevations may be present. This allows for early treatment, which can both prevent disease progression and decrease the likelihood of transmission to others.
Hepatitis A causes an acute illness that does not progress to chronic liver disease. Therefore, the role of screening is to assess immune status in people who are at high risk of contracting the virus, as well as in people with known liver disease for whom hepatitis A infection could lead to liver failure. People in these groups who are not already immune can receive the hepatitis A vaccine.
- People with poor sanitary habits such as not washing hands after using the restroom or changing diapers
- People who do not have access to clean water
- People in close contact (either living with or having sexual contact) with someone who has hepatitis A
- People who use illicit drugs
- People with liver disease
- People traveling to an area with endemic hepatitis A
- Born in countries where the prevalence of hepatitis B is high (defined as ≥2% of the population), whether or not they have been vaccinated
- Born in the United States whose parents are from countries where the prevalence of hepatitis B is very high (defined as ≥8% of the population), and who were not vaccinated
- HIV positive
- Intravenous drug users
- Men who have sex with men
- In close contact with (i.e. live or have sex with) people known to have hepatitis B
- Beginning immunosuppressive or cytotoxic therapy
- Found to have elevated liver enzymes without a known cause
- Blood, organ, or tissue donors
- On hemodialysis
Screening consists of a blood test that detects hepatitis B surface antigen (HBsAg). If HBsAg is present, a second test – usually done on the same blood sample – that detects the antibody for the hepatitis B core antigen (anti-HBcAg) can differentiate between acute and chronic infection. People who are high-risk whose blood tests negative for HBsAg can receive the hepatitis B vaccine to prevent future infection.
- Intravenous drug users (past or current)
- Intranasal illicit drug users
- Men who have sex with men
- Incarcerated, or who have been in the past
- On long-term hemodialysis, or who have been in the past
- Recipients of tattoos in an "unregulated setting"
- Recipients of blood products or organs prior to 1992 in the United States
- Adults in the United States born between 1945-1965
- Born to HCV-positive mothers
- Pregnant, and engaging in high-risk behaviors
- Workers in a healthcare setting who have had a needlestick injury
- Blood or organ donors.
- Sex workers
For people in the groups above whose exposure is ongoing, screening should be "periodic," though according to the USPSTF, research has not defined the optimal screening interval. The AASLD recommends screening men who have sex with men who are HIV-positive annually. People born in the US between 1945-1965 should be screened once (unless they have other exposure risks).
For children 12 months of age or older, the vaccination is given as a shot into the muscle in two doses 6–18 months apart and should be started before the age 24 months. The dosing is slightly different for adults depending on the type of the vaccine. If the vaccine is for hepatitis A only, two doses are given 6–18 months apart depending on the manufacturer. If the vaccine is combined hepatitis A and hepatitis B, up to 4 doses may be required.
Routine vaccination for hepatitis B starts with the first dose administered as a shot into the muscle before the newborn is discharged from the hospital. An additional two doses should be administered before the child is 18 months.
For babies born to a mother with hepatitis B surface antigen positivity, the first dose is unique – in addition to the vaccine, the hepatitis immune globulin should also be administered, both within 12 hours of birth. These newborns should also be regularly tested for infection for at least the first year of life.
There are currently no vaccines available in the United States for hepatitis C or E. In 2015, a group in China published an article regarding the development of a vaccine for hepatitis E. As of March 2016, the United States government was in the process of recruiting participants for the phase IV trial of the hepatitis E vaccine.
Hepatitis B and C
As hepatitis B and C are transmitted through blood and multiple bodily fluids, prevention is aimed at screening blood prior to transfusion, abstaining from the use of injection drugs, safe needle and sharps practices in healthcare settings, and safe sex practices.
The hepatitis D virus requires that a person first be infected with hepatitis B virus, so prevention efforts should focus on limiting the spread of hepatitis B. In people who have chronic hepatitis B infection and are at risk for superinfection with the hepatitis D virus, the preventive strategies are the same as for hepatitis B.
Hepatitis E is spread primarily through the oral-fecal route but may also be spread by blood and from mother to fetus. The mainstay of hepatitis E prevention is similar to that for hepatitis A (namely, good hygiene and clean water practices).
As excessive alcohol consumption can lead to hepatitis and cirrhosis, the following are maximal recommendations for alcohol consumption:
- Women – ≤ 3 drinks on any given day and ≤ 7 drinks per week
- Men – ≤ 4 drinks on any given day and ≤ 14 drinks per week
In the United States, universal immunization has led to a two-thirds decrease in hospital admissions and medical expenses due to hepatitis A.
In the United States new cases of hepatitis B decreased 75% from 1990–2004. The group that saw the greatest decrease was children and adolescents, likely reflecting the implementation of the 1999 guidelines.
Hepatitis C infections each year had been declining since the 1980s, but began to increase again in 2006. The data are unclear as to whether the decline can be attributed to needle exchange programmes.
Because people with alcoholic hepatitis may have no symptoms, it can be difficult to diagnose and the number of people with the disease is probably higher than many estimates. Programs such as Alcoholics Anonymous have been successful in decreasing death due to cirrhosis, but it is difficult to evaluate their success in decreasing the incidence of alcoholic hepatitis.
The treatment of hepatitis varies according to the type, whether it is acute or chronic, and the severity of the disease.
- Activity - Many people with hepatitis prefer bed rest, though it is not necessary to avoid all physical activity while recovering.
- Diet -A high-calorie diet is recommended. Many people develop nausea and cannot tolerate food later in the day, so the bulk of intake may be concentrated in the earlier part of the day. In the acute phase of the disease, intravenous feeding may be needed if patients cannot tolerate food and have poor oral intake subsequent to nausea and vomiting.
- Drugs - People with hepatitis should avoid taking drugs metabolized by the liver. Glucocorticoids are not recommended as a treatment option for acute viral hepatitis and may even cause harm, such as development of chronic hepatitis.
- Precautions - Universal precautions should be observed. Isolation is usually not needed, except in cases of hepatitis A and E who have fecal incontinence, and in cases of hepatitis B and C who have uncontrolled bleeding.
Hepatitis A usually does not progress to a chronic state, and rarely requires hospitalization. Treatment is supportive and includes such measures as providing intravenous (IV) hydration and maintaining adequate nutrition.
Rarely, people with the hepatitis A virus can rapidly develop liver failure, termed fulminant hepatic failure, especially the elderly and those who had a pre-existing liver disease, especially hepatitis C. Mortality risk factors include greater age and chronic hepatitis C. In these cases, more aggressive supportive therapy and liver transplant may be necessary.
In healthy patients, 95–99% recover with no long-lasting effects, and antiviral treatment is not warranted. Age and comorbid conditions can result in a more prolonged and severe illness. Certain patients warrant hospitalization, especially those who present with clinical signs of ascites, peripheral edema, and hepatic encephalopathy, and laboratory signs of hypoglycemia, prolonged prothrombin time, low serum albumin, and very high serum bilirubin.
In these rare, more severe acute cases, patients have been successfully treated with antiviral therapy similar to that used in cases of chronic hepatitis B, with nucleoside analogues such as entecavir or tenofovir. As there is a dearth of clinical trial data and the drugs used to treat are prone to developing resistance, experts recommend reserving treatment for severe acute cases, not mild to moderate.
- Injectable interferon alpha was the first therapy approved for chronic hepatitis B. It has several side effects, most of which are reversible with removal of therapy, but it has been supplanted by newer treatments for this indication. These include long-acting interferon bound to polyethylene glycol (pegylated interferon) and the oral nucleoside analogues.
- Pegylated interferon (PEG IFN) is dosed just once a week as a subcutaneous injection and is both more convenient and effective than standard interferon. Although it does not develop resistance as do many of the oral antivirals, it is poorly tolerated and requires close monitoring. PEG IFN is estimated to cost about $18,000 per year in the United States, compared to $2,500-8,700 for the oral medications; however, its treatment duration is 48 weeks as opposed to the oral antivirals, which require indefinite treatment for most patients (minimum 1 year). PEG IFN is not effective in patients with high levels of viral activity and cannot be used in immunosuppressed patients or those with cirrhosis.
- Lamivudine was the first approved oral nucleoside analogue. While effective and potent, lamivudine has been replaced by newer, more potent treatments in the Western world and is no longer recommended as first-line treatment. However, it is still used in areas where newer agents either have not been approved or are too costly. Generally, the course of treatment is a minimum of one year with a minimum of six additional months of "consolidation therapy." Based on viral response, longer therapy may be required, and certain patients require indefinite long-term therapy. Due to a less robust response in Asian patients, consolidation therapy is recommended to be extended to at least a year. All patients should be monitored for viral reactivation, which if identified, requires restarting treatment. Lamivudine is generally safe and well tolerated. Many patients develop resistance, which is correlated with longer treatment duration. If this occurs, an additional antiviral is added. Lamivudine as a single treatment is contraindicated in patients coinfected with HIV, as resistance develops rapidly, but it can be used as part of a multidrug regimen.
- Adefovir dipivoxil, a nucleotide analogue, has been used to supplement lamivudine in patients who develop resistance, but is no longer recommended as first-line therapy.
- Entecavir is safe, well tolerated, less prone to developing resistance, and the most potent of the existing hepatitis B antivirals; it is thus a first-line treatment choice. It is not recommended for lamivudine-resistant patients or as monotherapy in patients who are HIV positive.
- Telbivudine is effective but not recommended as first-line treatment; as compared to entecavir, it is both less potent and more resistance prone.
- Tenofovir is a nucleotide analogue and an antiretroviral drug that is also used to treat HIV infection. It is preferred to adefovir both in lamivudine-resistant patients and as initial treatment since it is both more potent and less likely to develop resistance.
First-line treatments currently used include PEG IFN, entecavir, and tenofovir, subject to patient and physician preference. Treatment initiation is guided by recommendations issued by The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) and is based on detectable viral levels, HBeAg positive or negative status, ALT levels, and in certain cases, family history of HCC and liver biopsy. In patients with compensated cirrhosis, treatment is recommended regardless of HBeAg status or ALT level, but recommendations differ regarding HBV DNA levels; AASLD recommends treating at DNA levels detectable above 2x103 IU/mL; EASL and WHO recommend treating when HBV DNA levels are detectable at any level. In patients with decompensated cirrhosis, treatment and evaluation for liver transplantation are recommended in all cases if HBV DNA is detectable. Currently, multidrug treatment is not recommended in treatment of chronic HBV as it is no more effective in the long term than individual treatment with entecavir or tenofovir.
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD-IDSA) recommend antiviral treatment for all patients with chronic hepatitis C infection except for those with additional chronic medical conditions that limit their life expectancy.
Once it is acquired, persistence of the hepatitis C virus is the rule, resulting in chronic hepatitis C. The goal of treatment is prevention of hepatocellular carcinoma (HCC). The best way to reduce the long-term risk of HCC is to achieve sustained virological response (SVR). SVR is defined as an undetectable viral load at 12 weeks after treatment completion and indicates a cure. Currently available treatments include indirect and direct acting antiviral drugs. The indirect acting antivirals include pegylated interferon (PEG IFN) and ribavirin (RBV), which in combination have historically been the basis of therapy for HCV. Duration of and response to these treatments varies based on genotype. These agents are poorly tolerated but are still used in some resource-poor areas. In high-resource countries, they have been supplanted by direct acting antiviral agents, which first appeared in 2011; these agents target proteins responsible for viral replication and include the following three classes:
- NS3/4A protease inhibitors, including telaprevir, boceprevir, simeprevir, and others
- NS5A inhibitors, including ledipasvir, daclatasvir, and others
- NS5B polymerase inhibitors, including sofosbuvir, dasabuvir, and others
These drugs are used in various combinations, sometimes combined with ribavirin, based on the patient's genotype, delineated as genotypes 1–6. Genotype 1 (GT1), which is the most prevalent genotype in the United States and around the world, can now be cured with a direct acting antiviral regimen. First-line therapy for GT1 is a combination of sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks for most patients, including those with advanced fibrosis or cirrhosis. Certain patients with early disease need only 8 weeks of treatment while those with advanced fibrosis or cirrhosis who have not responded to prior treatment require 24 weeks. Cost remains a major factor limiting access to these drugs, particularly in low-resource nations; the cost of the 12-week GT1 regimen (SOF/LDV) has been estimated at US$94,500.
Hepatitis D is difficult to treat, and effective treatments are lacking. Interferon alpha has proven effective at inhibiting viral activity but only on a temporary basis.
Similar to hepatitis A, treatment of hepatitis E is supportive and includes rest and ensuring adequate nutrition and hydration. Hospitalization may be required for particularly severe cases or for pregnant women.
First-line treatment of alcoholic hepatitis is treatment of alcoholism. For those who abstain completely from alcohol, reversal of liver disease and a longer life are possible; patients at every disease stage have been shown to benefit by prevention of additional liver injury. In addition to referral to psychotherapy and other treatment programs, treatment should include nutritional and psychosocial evaluation and treatment. Patients should also be treated appropriately for related signs and symptoms, such as ascites, hepatic encephalopathy, and infection.
Severe alcoholic hepatitis has a poor prognosis and is notoriously difficult to treat. Without any treatment, 20-50% of patients may die within a month, but evidence shows treatment may extend life beyond one month (i.e., reduce short-term mortality). Available treatment options include pentoxifylline (PTX), which is a nonspecific TNF inhibitor, corticosteroids, such as prednisone or prednisolone (CS), corticosteroids with N-acetylcysteine (CS with NAC), and corticosteroids with pentoxifylline (CS with PTX). Data suggest that CS alone or CS with NAC are most effective at reducing short-term mortality. Unfortunately, corticosteroids are contraindicated in some patients, such as those who have active gastrointestinal bleeding, infection, kidney failure, or pancreatitis. In these cases PTX may be considered on a case by case basis in lieu of CS; some evidence shows PTX is better than no treatment at all and may be comparable to CS while other data show no evidence of benefit over placebo. Unfortunately, there are currently no drug treatments that decrease these patients’ risk of dying in the longer term, at 3–12 months and beyond.
Weak evidence suggests milk thistle extracts may improve survival in alcoholic liver disease and improve certain liver tests (serum bilirubin and GGT) without causing side effects, but a firm recommendation cannot be made for or against milk thistle without further study.
Nearly all patients with hepatitis A infections recover completely without complications if they were healthy prior to the infection. Similarly, acute hepatitis B infections have a favorable course towards complete recovery in 95–99% of patients. However, certain factors may portend a poorer outcome, such as co-morbid medical conditions or initial presenting symptoms of ascites, edema, or encephalopathy. Overall, the mortality rate for acute hepatitis is low: ~0.1% in total for cases of hepatitis A and B, but rates can be higher in certain populations (super infection with both hepatitis B and D, pregnant women, etc.).
In contrast to hepatitis A & B, hepatitis C carries a much higher risk of progressing to chronic hepatitis, approaching 85–90%. Cirrhosis has been reported to develop in 20–50% of patients with chronic hepatitis C.
Despite the relatively benign course of most viral cases of hepatitis, fulminant hepatitis represents a rare but feared complication. Fulminant hepatitis most commonly occurs in hepatitis B, D, and E. About 1–2% of cases of hepatitis E can lead to fulminant hepatitis, but pregnant women are particularly susceptible, occurring in up to 20% of cases. Mortality rates in cases of fulminant hepatitis rise over 80%, but those patients that do survive often make a complete recovery. Liver transplantation can be life-saving in patients with fulminant liver failure.
Acute hepatitis B infections become less likely to progress to chronic forms as the age of the patient increases, with rates of progression approaching 90% in vertically transmitted cases of infants compared to 1% risk in young adults. Overall, the 5-year survival rate for chronic hepatitis B ranges from 97% in mild cases to 55% in severe cases with cirrhosis.
Most patients who acquire hepatitis D at the same time as hepatitis B (co-infection) recover without developing a chronic infection; however, in people with hepatitis B who later acquire hepatitis D (superinfection), chronic infection is much more common at 80-90%, and liver disease progression is accelerated.
Chronic hepatitis C progresses towards cirrhosis, with estimates of cirrhosis prevalence of 16% at 20 years after infection. While the major causes of mortality in hepatitis C is end stage liver disease, hepatocellular carcinoma is an important additional long term complication and cause of death in chronic hepatitis.
Rates of mortality increase with progression of the underlying liver disease. Series of patients with compensated cirrhosis due to HCV have shown 3,5, and 10-year survival rates of 96, 91, and 79% respectively. The 5-year survival rate drops to 50% upon if the cirrhosis becomes decompensated.
Hepatitis A is found throughout the world and manifests as large outbreaks and epidemics associated with fecal contamination of water and food sources. Hepatitis A viral infection is predominant in children ages 5–14 with rare infection of infants. Infected children have little to no apparent clinical illness, in contrast to adults in whom greater than 80% are symptomatic if infected. Infection rates are highest in low resource countries with inadequate public sanitation and large concentrated populations. In such regions, as much as 90% of children younger than 10 years old have been infected and are immune, corresponding both to lower rates of clinically symptomatic disease and outbreaks. The availability of a childhood vaccine has significantly reduced infections in the United States, with incidence declining by more than 95% as of 2013. Paradoxically, the highest rates of new infection now occur in young adults and adults who present with worse clinical illness. Specific populations at greatest risk include: travelers to endemic regions, men who have sex with men, those with occupational exposure to non-human primates, individuals with clotting disorders who have received clotting factors, individuals with a history of chronic liver disease where co-infection with hepatitis A can lead to fulminant hepatitis, and intravenous drug users (rare).
Hepatitis B is the most common cause of viral hepatitis in the world with more than 240 million chronic carriers of the virus, 1 million of whom are in the United States. In approximately two-thirds of patients who develop acute hepatitis B infection, no identifiable exposure is evident. Of those acutely infected, 25% become lifetime carriers of the virus. Risk of infection is highest among intravenous drug users, individuals with high-risk sexual behaviors, healthcare workers, individuals with a history of multiple transfusions, organ transplant patients, dialysis patients and newborns infected during the birthing process. Close to 780,000 deaths in the world are attributed to hepatitis B. The most endemic regions are in sub-Saharan Africa and East Asia, where as many as 10% of adults are chronic carriers. Carrier rates in developed nations are significantly lower, encompassing less than 1% of the population. In endemic regions, transmission is thought to be associated with exposure during birth and close contact between young infants.
Chronic hepatitis C is a major cause of liver cirrhosis and hepatocellular carcinoma. It is a common medical reason for liver transplantation due to its severe complications. It is estimated that 130–180 million people in the world are affected by this disease representing a little more than 3% of the world population. In the developing regions of Africa, Asia and South America, prevalence can be as high as 10% of the population. In Egypt, rates of hepatitis C infection as high as 20% have been documented and are associated with iatrogenic contamination related to schistosomiasis treatment in the 1950s–1980s. Currently in the United States, approximately 3.5 million adults are estimated to be infected. Hepatitis C is particularly prevalent among people born between 1945–1965, a group of about 800,000 people, with prevalence as high as 3.2% versus 1.6% in the general U.S. population. Most chronic carriers of hepatitis C are unaware of their infection status. The most common mode of transmission of hepatitis C virus is exposure to blood products via blood transfusions (prior to 1992) and intravenous drug injection. A history of intravenous drug injection is the most important risk factor for chronic hepatitis C. Other susceptible populations include individuals with high-risk sexual behavior, infants of infected mothers, and healthcare workers.
The hepatitis D virus causes chronic and fulminant hepatitis in the context of co-infection with the hepatitis B virus. It is primarily transmitted via non-sexual contact and via needles. Susceptibility to hepatitis D differs by geographic region. In the United States and Northern Europe, populations at risk are intravenous drug users and individuals who receive multiple transfusions. In the Mediterranean, hepatitis D is predominant among hepatitis B virus co-infected individuals.
Similar to Hepatitis A, hepatitis E manifests as large outbreaks and epidemics associated with fecal contamination of water sources. It accounts for more than 55,000 deaths annually with approximately 20 million people worldwide thought to be infected with the virus. It affects predominantly young adults, causing acute hepatitis. In infected pregnant women, Hepatitis E infection can lead to fulminant hepatitis with third trimester mortality rates as high as 30%. Individuals with weakened immune systems, such as organ transplant recipients, are also susceptible. Infection is rare in the United States but rates are high in the developing world (Africa, Asia, Central America, Middle East). Many genotypes exist and are differentially distributed around the world. There is some evidence of hepatitis E infection of animals, serving as a reservoir for human infection.
Alcoholic hepatitis (AH) in its severe form has a one-month mortality as high as 50%. Most people who develop AH are men but women are at higher risk of developing AH and its complications likely secondary to high body fat and differences in alcohol metabolism. Other contributing factors include younger age <60, binge pattern drinking, poor nutritional status, obesity and hepatitis C co-infection. It is estimated that as much as 20% of people with AH are also infected with hepatitis C. In this population, the presence of hepatitis C virus leads to more severe disease with faster progression to cirrhosis, hepatocellular carcinoma and increased mortality. Obesity increases the likelihood of progression to cirrhosis in individuals with alcoholic hepatitis. It is estimated that a high proportion of individuals (70%) who have AH will progress to cirrhosis.
Non-alcoholic steatohepatitis (NASH) is projected to become the top reason for liver transplantation in the United States by the year 2020, supplanting chronic liver disease due to hepatitis C. About 20–45% of the U.S. population have NAFLD and 6% have NASH. The estimated prevalence of NASH in the world is 3–5%. Of NASH patients who develop cirrhosis, about 2% per year will likely progress to hepatocellular carcinoma. Worldwide, the estimated prevalence of hepatocellular carcinoma related to NAFLD is 15–30%. NASH is thought to be the primary cause of cirrhosis in approximately 25% of patients in the United States, representing 1–2% of the general population.
Initial accounts of a syndrome that we now think is likely to be hepatitis begin to occur around 3000 B.C. Clay tablets that served as medical handbooks for the ancient Sumerians described the first observations of jaundice. The Sumerians believed that the liver was the home of the soul, and attributed the findings of jaundice to the attack of the liver by a devil named Ahhazu.
Around 400 B.C., Hippocrates recorded the first documentation of an epidemic jaundice, in particular noting the uniquely fulminant course of a cohort of patients who all died within two weeks. He wrote, “The bile contained in the liver is full of phlegm and blood, and erupts...After such an eruption, the patient soon raves, becomes angry, talks nonsense and barks like a dog.”
Given the poor sanitary conditions of war, infectious jaundice played a large role as a major cause of mortality among troops in the Napoleonic Wars, the American Revolutionary War, and both World Wars. During World War II, estimates of soldiers affected by hepatitis were upwards of 10 million.
During World War II, soldiers received vaccines against diseases such as yellow fever, but these vaccines were stabilized with human serum, presumably contaminated with hepatitis viruses, which often created epidemics of hepatitis. It was suspected these epidemics were due to a separate infectious agent, and not due to the yellow fever virus itself, after noting 89 cases of jaundice in the months after vaccination out of a total 3,100 patients that were vaccinated. After changing the seed virus strain, no cases of jaundice were observed in the subsequent 8,000 vaccinations.
Willowbrook State School experiments
A New York University researcher named Saul Krugman continued this research into the 1950s and 1960s, most infamously with his experiments on mentally disabled children at the Willowbrook State School in New York, a crowded urban facility where hepatitis infections were highly endemic to the student body. Krugman injected students with gamma globulin, a type of antibody. After observing the temporary protection against infection this antibody provided, he then tried injected live hepatitis virus into students. Krugman also controversially took feces from infected students, blended it into milkshakes, and fed it to newly admitted children.
His research was received with much controversy, as people protested the questionable ethics surrounding the chosen target population. Henry Beecher was one of the foremost critics in an article in the New England Journal of Medicine in 1966, arguing that parents were unaware to the risks of consent and that the research was done to benefit others at the expense of children. Moreover, he argued that poor families with mentally disabled children often felt pressured to join the research project to gain admission to the school, with all of the educational and support resources that would come along with it. Others in the medical community spoke out in support of Krugman's research in terms of its widespread benefits and understanding of the hepatitis virus, and Willowbrook continues to be a commonly cited example in debates about medical ethics.
The Australia antigen
The next insight regarding hepatitis B was a serendipitous one by Dr. Baruch Blumberg, a researcher at the NIH who did not set out to research hepatitis, but rather studied lipoprotein genetics. He travelled across the globe collecting blood samples, investigating the interplay between disease, environment, and genetics with the goal of designing targeted interventions for at-risk individuals that could prevent them from getting sick. He noticed an unexpected interaction between the blood of a patient with hemophilia that had received multiple transfusions and a protein found in the blood of an Australian aborigine. He named the protein the "Australia antigen" and made it the focus of his research. He found a higher prevalence of the protein in the blood of patients from developing countries, compared to those from developed ones, and noted associations of the antigen with other diseases like leukemia and Down Syndrome. Eventually, he came to the unifying conclusion that the Australia antigen was associated with viral hepatitis.
In 1970, David Dane first isolated the hepatitis B virion at London's Middlesex Hospital, and named the virion the 42-nm "Dane particle". Based on its association with the surface of the hepatitis B virus, the Australia antigen was renamed to "hepatitis B surface antigen" or HBsAg.
Society and culture
Overall, hepatitis accounts for a significant portion of healthcare expenditures in both developing and developed nations, and is expected to rise in several developing countries. While hepatitis A infections are self-limited events, they are associated with significant costs in the United States. It has been estimated that direct and indirect costs are approximately $1817 and $2459 respectively per case, and that an average of 27 work days is lost per infected adult. A 1997 report demonstrated that a single hospitalization related to hepatitis A cost an average of $6,900 and resulted in around $500 million in total annual healthcare costs. Cost effectiveness studies have found widespread vaccination of adults to not be feasible, but have stated that a combination hepatitis A and B vaccination of children and at risk groups (people from endemic areas, healthcare workers) may be.
Hepatitis B accounts for a much larger percentage of health care spending in endemic regions like Asia. In 1997 it accounted for 3.2% of South Korea's total health care expenditures and resulted in $696 million in direct costs. A large majority of that sum was spent on treating disease symptoms and complications. Chronic hepatitis B infections are not as endemic in the United States, but accounted for $357 million in hospitalization costs in the year 1990. That number grew to $1.5 billion in 2003, but remained stable as of 2006, which may be attributable to the introduction of effective drug therapies and vaccination campaigns.
People infected with chronic hepatitis C tend to be frequent users of the health care system globally. It has been estimated that a person infected with hepatitis C in the United States will result in a monthly cost of $691. That number nearly doubles to $1,227 for people with compensated (stable) cirrhosis, while the monthly cost of people with decompensated (worsening) cirrhosis is almost five times as large at $3,682. The wide-ranging effects of hepatitis make it difficult to estimate indirect costs, but studies have speculated that the total cost is $6.5 billion annually in the United States. In Canada, 56% of HCV related costs are attributable to cirrhosis and total expenditures related to the virus are expected to peak at CAD$396 million in the year 2032.
The largest outbreak of hepatitis A virus in United States history occurred among people who ate at a now-defunct Mexican food restaurant located in Monaca, Pennsylvania in late 2003. Over 550 people who visited the restaurant between September and October 2003 were infected with the virus, three of whom died as a direct result. The outbreak was brought to the attention of health officials when local emergency medicine physicians noticed a significant increase in cases of hepatitis A in the county. After conducting its investigation, the CDC attributed the source of the outbreak to the use of contaminated raw green onion. The restaurant was purchasing its green onion stock from farms in Mexico at the time. It is believed that the green onions may have been contaminated through the use of contaminated water for crop irrigation, rinsing, or icing or by handling of the vegetables by infected individuals. Green onion had caused similar outbreaks of hepatitis A in the southern United States prior to this, but not to the same magnitude. The CDC believes that the restaurant's use of a large communal bucket for chopped raw green onion allowed non-contaminated plants to be mixed with contaminated ones, increasing the number of vectors of infection and amplifying the outbreak. The restaurant was closed once it was discovered to be the source, and over 9,000 people were given hepatitis A immune globulin because they had either eaten at the restaurant or had been in close contact with someone who had.
Persons infected with HIV have a particularly high burden of HIV-HCV co-infection. In a recent study by the WHO, the likelihood of being infected with hepatitis C virus was six times greater in individuals who also had HIV. The prevalence of HIV-HCV co-infection worldwide was estimated to be 6.2% representing more than 2.2 million people. Intravenous drug use was an independent risk factor for HCV infection. In the WHO study, the prevalence of HIV-HCV co-infection was markedly higher at 82.4% in those who injected drugs compared to the general population (2.4%). In a study of HIV-HCV co-infection among HIV positive men who have sex with men (MSM), the overall prevalence of anti-hepatitis C antibodies was estimated to be 8.1% and increased to 40% among HIV positive MSM who also injected drugs.
Vertical transmission is a significant contributor of new HBV cases each year, with 35–50% of transmission from mother to neonate in endemic countries. Vertical transmission occurs largely via a neonate's exposure to maternal blood and vaginal secretions during birth. While the risk of progression to chronic infection is approximately 5% among adults who contract the virus, it is as high as 95% among neonates subject to vertical transmission. The risk of viral transmission is approximately 10–20% when maternal blood is positive for HBsAg, and up to 90% when also positive for HBeAg.
Given the high risk of perinatal transmission, the CDC recommends screening all pregnant women for HBV at their first prenatal visit. It is safe for non-immune pregnant women to receive the HBV vaccine. Based on the limited available evidence, the American Association for the Study of Liver Diseases (AASLD) recommends antiviral therapy in pregnant women whose viral load exceeds 200,000 IU/mL. A growing body of evidence shows that antiviral therapy initiated in the third trimester significantly reduces transmission to the neonate. A systematic review of the Antiretroviral Pregnancy Registry database found that there was no increased risk of congenital anomalies with Tenofovir; for this reason, along with its potency and low risk of resistance, the AASLD recommends this drug. A 2010 systematic review and meta-analysis found that Lamivudine initiated early in the third trimester also significantly reduced mother-to-child transmission of HBV, without any known adverse effects.
The WHO and CDC recommend that neonates born to mothers with HBV should receive hepatitis B immune globulin (HBIG) as well as the HBV vaccine within 12 hours of birth. For infants who have received HBIG and the HBV vaccine, breastfeeding is safe.
Estimates of the rate of HCV vertical transmission range from 2–8%; a 2014 systematic review and meta-analysis found the risk to be 5.8% in HCV-positive, HIV-negative women. The same study found the risk of vertical transmission to be 10.8% in HCV-positive, HIV-positive women. Other studies have found the risk of vertical transmission to be as high as 44% among HIV-positive women. The risk of vertical transmission is higher when the virus is detectable in the mother's blood.
Evidence does not indicate that mode of delivery (i.e. vaginal vs. cesarean) has an effect on vertical transmission.
For women who are HCV-positive and HIV-negative, breastfeeding is safe; however, CDC guidelines suggest avoiding breastfeeding if a woman's nipples are "cracked or bleeding" to reduce the risk of transmission.
Pregnant women who contract HEV are at significant risk of developing fulminant hepatitis with maternal mortality rates as high as 20–30%, most commonly in the third trimester . A 2016 systematic review and meta-analysis of 47 studies that included 3968 people found maternal case-fatality rates (CFR) of 20.8% and fetal CFR of 34.2%; among women who developed fulminant hepatic failure, CFR was 61.2%.
- "Hepatitis". MedlinePlus. Archived from the original on 11 November 2016. Retrieved 10 November 2016.
- "What is hepatitis?". WHO. July 2016. Archived from the original on 7 November 2016. Retrieved 10 November 2016.
- "Hepatitis". NIAID. Archived from the original on 4 November 2016. Retrieved 2 November 2016.
- "Liver Transplant". NIDDK. April 2012. Archived from the original on 11 November 2016. Retrieved 10 November 2016.
- "Hepatitis (Hepatitis A, B, and C) | ACG Patients". patients.gi.org. Archived from the original on 2017-02-23.
- Bernal W.; Wendon J. (2013). "Acute Liver Failure". New England Journal of Medicine. 369 (26): 2525–2534. doi:10.1056/nejmra1208937. PMID 24369077.
- "Fatty Liver Disease (Nonalcoholic Steatohepatitis)". NIDDK. May 2014. Archived from the original on 11 November 2016. Retrieved 10 November 2016.
- AASLD/IDSA HCV Guidance Panel (2015-09-01). "Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus". Hepatology. 62 (3): 932–954. doi:10.1002/hep.27950. ISSN 1527-3350. PMID 26111063.
- "Autoimmune Hepatitis". NIDDK. March 2014. Archived from the original on 11 November 2016. Retrieved 10 November 2016.
- Vos, Theo; Allen, Christine; Arora, Megha; Barber, Ryan M.; Bhutta, Zulfiqar A.; Brown, Alexandria; Carter, Austin; Casey, Daniel C.; Charlson, Fiona J.; Chen, Alan Z.; Coggeshall, Megan; Cornaby, Leslie; Dandona, Lalit; Dicker, Daniel J.; Dilegge, Tina; Erskine, Holly E.; Ferrari, Alize J.; Fitzmaurice, Christina; Fleming, Tom; Forouzanfar, Mohammad H.; Fullman, Nancy; Gething, Peter W.; Goldberg, Ellen M.; Graetz, Nicholas; Haagsma, Juanita A.; Hay, Simon I.; Johnson, Catherine O.; Kassebaum, Nicholas J.; Kawashima, Toana; Kemmer, Laura (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". The Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282. Unknown parameter
- Basra, Sarpreet (2011). "Definition, epidemiology and magnitude of alcoholic hepatitis". World Journal of Hepatology. 3 (5): 108–13. doi:10.4254/wjh.v3.i5.108. PMC 3124876. PMID 21731902.
- Wang, Haidong; Naghavi, Mohsen; Allen, Christine; Barber, Ryan M.; Bhutta, Zulfiqar A.; Carter, Austin; Casey, Daniel C.; Charlson, Fiona J.; Chen, Alan Zian; Coates, Matthew M.; Coggeshall, Megan; Dandona, Lalit; Dicker, Daniel J.; Erskine, Holly E.; Ferrari, Alize J.; Fitzmaurice, Christina; Foreman, Kyle; Forouzanfar, Mohammad H.; Fraser, Maya S.; Fullman, Nancy; Gething, Peter W.; Goldberg, Ellen M.; Graetz, Nicholas; Haagsma, Juanita A.; Hay, Simon I.; Huynh, Chantal; Johnson, Catherine O.; Kassebaum, Nicholas J.; Kinfu, Yohannes; Kulikoff, Xie Rachel (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". The Lancet. 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1. PMC 5388903. PMID 27733281. Unknown parameter
- "Statistics & Surveillance Division of Viral Hepatitis CDC". CDC. Archived from the original on 11 November 2016. Retrieved 10 November 2016.
- "Online Etymology Dictionary". Etymonline.com. Archived from the original on 2012-10-20. Retrieved 2012-08-26.
- Dienstag, JL (2015). "Chapter 360: Acute Viral Hepatitis". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). Harrison's Principles of Internal Medicine, 19e. New York, NY: McGraw-Hill. ISBN 978-0-07-180215-4.
- Rutherford, A; Dienstag, JL (2016). "Chapter 40: Viral Hepatitis". In Greenberger, NJ; Blumberg, RS; Burakoff, R (eds.). CURRENT Diagnosis & Treatment: Gastroenterology, Hepatology, & Endoscopy, 3e. New York, NY: McGraw-Hill. ISBN 978-0-07-183772-9.
- Khalili, M; Burman, B (2013). "Chapter 14: Liver Disease". In Hammer, GD; McPhee, SJ (eds.). Pathophysiology of Disease: An Introduction to Clinical Medicine, 7e. McGraw-Hill. ISBN 978-1-25-925144-3.
- Dienstag, JL (2015). "Chapter 362: Chronic Hepatitis". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). Harrison's Principles of Internal Medicine, 19e. New York, NY: McGraw-Hill. ISBN 978-0-07-180215-4.
- Fontana, Robert; Hayashi, Paul (2014-05-01). "Clinical Features, Diagnosis, and Natural History of Drug-Induced Liver Injury". Seminars in Liver Disease. 34 (2): 134–144. doi:10.1055/s-0034-1375955. PMID 24879979.
- Manns, Michael P.; Lohse, Ansgar W.; Vergani, Diego (2015). "Autoimmune hepatitis – Update 2015". Journal of Hepatology. 62 (1): S100–S111. doi:10.1016/j.jhep.2015.03.005. PMID 25920079.
- Munjal, Y. P.; Sharm, Surendra K. (2012). API Textbook of Medicine, Ninth Edition, Two Volume Set. JP Medical Ltd. p. 870. ISBN 9789350250747. Archived from the original on 2017-09-10.
- World Health Organization. "Hepatitis". World Health Organization. Archived from the original on 2 December 2013. Retrieved 25 November 2013.
- "Hepatitis A Questions and Answers for the Public | Division of Viral Hepatitis | CDC". www.cdc.gov. Archived from the original on 2016-03-12. Retrieved 2016-03-14.
- "Hepatitis E". World Health Organization. Archived from the original on 2016-03-12. Retrieved 2016-03-14.
- Centers for Disease Control & Prevention (June 2010). "When Someone Close to You Has Hepatitis" (PDF). Archived (PDF) from the original on March 6, 2016. Retrieved March 14, 2016.
- "Hepatitis B". World Health Organization. Archived from the original on 2014-11-09. Retrieved 2016-03-09.
- "Hepatitis C FAQs for the Public | Division of Viral Hepatitis | CDC". www.cdc.gov. Archived from the original on 2016-03-15. Retrieved 2016-03-14.
- Friedman, Lawrence S. (2015). "Chapter 16: Liver, Biliary Tract, & Pancreas Disorders". In Papadakis, M; McPhee, SJ; Rabow, MW (eds.). Current Medical Diagnosis & Treatment 2016 55e. McGraw Hill. ISBN 978-0071845090.
- Harder, A; Mehlhorn, H (2008). "Diseases Caused by Adult Parasites or Their Distinct Life Cycle Stages". In Weber, O; Protzer, U (eds.). Comparative Hepatitis. Birkhauser. pp. 161–216. ISBN 978-3764385576.
- Wisplinghoff, H; Appleton, DL (2008). "Bacterial Infections of the Liver". In Weber, O; Protzer, U (eds.). Comparative Hepatitis. Birkhauser. pp. 143–160. ISBN 978-3764385576.
- Mailliard, ME; Sorrell, MF (2015). "Chapter 363: Alcoholic Liver Disease". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). Harrison's Principles of Internal Medicine 19e. McGraw-Hill. ISBN 978-0-07-180215-4.
- Lee, WM; Dienstag, JL (2015). "Chapter 361: Toxic and Drug-Induced Hepatitis". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). Harrison's Principles of Internal Medicine 19e. McGraw-Hill. ISBN 978-0-07-180215-4.
- Malaguarnera, Giulia; Cataudella, E; Giordano, M; Nunnari, G; Chisari, G; Malaguarnera, M (2012). "Toxic hepatitis in occupational exposure to solvents". World Journal of Gastroenterology. 18 (22): 2756–66. doi:10.3748/wjg.v18.i22.2756. PMC 3374978. PMID 22719183.
- Lee, William M. (31 July 2003). "Drug-Induced Hepatotoxicity". New England Journal of Medicine. 349 (5): 474–485. doi:10.1056/NEJMra021844. PMID 12890847.
- Suk, Ki Tae; Kim, Dong Joon (2012). "Drug-induced liver injury: present and future". Clinical and Molecular Hepatology. 18 (3): 249–57. doi:10.3350/cmh.2012.18.3.249. PMC 3467427. PMID 23091804.
- "Herbals_and_Dietary_Supplements". livertox.nih.gov. Archived from the original on 2016-05-08. Retrieved 2016-03-14.
- "NIH launches free database of drugs associated with liver injury". National Institutes of Health (NIH). 2015-09-30. Retrieved 2018-09-18.
- O'Mara SR, Gebreyes K (2011). "Chapter 83. Hepatic Disorders, Jaundice, and Hepatic Failure" (Online). In Cydulka RK, Meckler GD (eds.). Tintinalli's Emergency Medicine: A Comprehensive Study Guide (7th ed.). New York: McGraw-Hill. Archived from the original on 2 December 2013. Retrieved 26 November 2013.
- Abdelmalek, MF; Diehl AM (2015). "Chapter 364: Nonalcoholic Liver Diseases and Nonalcoholic Steatohepatitis". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). Harrison's Principles of Internal Medicine 19e. McGraw-Hill. ISBN 978-0-07-180215-4.
- National Digestive Diseases Information Clearinghouse (NDDIC). "Nonalcoholic Steatohepatitis". National Digestive Diseases Information Clearinghouse (NDDIC). Archived from the original on 2 December 2013. Retrieved 27 November 2013.
- Masuoka, Howard C.; Chalasani, Naga (April 2013). "Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals". Annals of the New York Academy of Sciences. 1281 (1): 106–122. Bibcode:2013NYASA1281..106M. doi:10.1111/nyas.12016. PMC 3646408. PMID 23363012.
- National Digestive Diseases Information Clearinghouse (NDDIC). "Autoimmune Hepatitis". National Digestive Diseases Information Clearinghouse (NDDIC). Archived from the original on 15 September 2010. Retrieved 27 November 2013.
- Teufel, Andreas; Galle, PR; Kanzler, S (2009). "Update on autoimmune hepatitis". World Journal of Gastroenterology. 15 (9): 1035–41. doi:10.3748/wjg.15.1035. PMC 2655176. PMID 19266594.
- Czaja, Albert J (2016). "Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions". Gut and Liver. 10 (2): 177–203. doi:10.5009/gnl15352. PMC 4780448. PMID 26934884.
- Krawitt, Edward-L (2008). "Clinical features and management of autoimmune hepatitis". World Journal of Gastroenterology. 14 (21): 3301–5. doi:10.3748/wjg.14.3301. PMC 2716584. PMID 18528927.
- Teckman, Jeffrey H. (2013-03-07). "Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Understanding and Future Therapy". COPD: Journal of Chronic Obstructive Pulmonary Disease. 10 (sup1): 35–43. doi:10.3109/15412555.2013.765839. ISSN 1541-2555. PMID 23527737.
- Medline Plus (2012-08-10). "Hepatic ischemia". National Library of Medicine. Archived from the original on 8 December 2013. Retrieved 4 December 2013.
- Feldman, Friedman; Feldman, Brandt, eds. (2010). "Chapter 83 Vascular Diseases of the Liver" (Online). Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Saunders. ISBN 978-1416061892. Archived from the original on 4 March 2016. Retrieved 4 December 2013.
- Samyn, M; Mieli-Vergani, G (November 2015). "Liver and Biliary Disease in Infancy". Medicine. 43 (11): 625–630. doi:10.1016/j.mpmed.2015.08.008.
- Roberts, Eve A. (2003-10-01). "Neonatal hepatitis syndrome". Seminars in Neonatology: SN. 8 (5): 357–374. doi:10.1016/S1084-2756(03)00093-9. ISSN 1084-2756. PMID 15001124.
- Sokol, Ronald J.; Narkewicz, Michael R. (2012-06-21). "Chapter 22: Liver & Pancreas". In Hay, William W. (ed.). Current diagnosis & treatment: pediatrics (21st ed.). New York: McGraw-Hill Medical. ISBN 978-0-07-177970-8. Archived from the original on 10 December 2013. Retrieved 2 December 2013. Unknown parameter
- Alexopoulou, Alexandra; Deutsch, Melanie; Ageletopoulou, Johanna; Delladetsima, Johanna K.; Marinos, Evangelos; Kapranos, Nikiforos; Dourakis, Spyros P. (May 2003). "A fatal case of postinfantile giant cell hepatitis in a patient with chronic lymphocytic leukaemia". European Journal of Gastroenterology & Hepatology. 15 (5): 551–555. doi:10.1097/01.meg.0000050026.34359.7c. PMID 12702915.
- Nakamoto, Yasunari; Kaneko, Shuichi (2003-09-01). "Mechanisms of viral hepatitis induced liver injury". Current Molecular Medicine. 3 (6): 537–544. doi:10.2174/1566524033479591. ISSN 1566-5240. PMID 14527085.
- Wong, Grace Lai-Hung (2014-09-01). "Prediction of fibrosis progression in chronic viral hepatitis". Clinical and Molecular Hepatology. 20 (3): 228–236. doi:10.3350/cmh.2014.20.3.228. ISSN 2287-285X. PMC 4197170. PMID 25320725.
- Rehermann, Barbara (2015-11-01). "Natural Killer Cells in Viral Hepatitis". Cellular and Molecular Gastroenterology and Hepatology. 1 (6): 578–588. doi:10.1016/j.jcmgh.2015.09.004. ISSN 2352-345X. PMC 4678927. PMID 26682281.
- Heim, Markus H.; Thimme, Robert (2014-11-01). "Innate and adaptive immune responses in HCV infections". Journal of Hepatology. 61 (1 Suppl): S14–25. doi:10.1016/j.jhep.2014.06.035. ISSN 1600-0641. PMID 25443342.
- Hardy, Timothy; Oakley, Fiona; Anstee, Quentin M.; Day, Christopher P. (2016-03-03). "Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum". Annual Review of Pathology. 11: 451–96. doi:10.1146/annurev-pathol-012615-044224. ISSN 1553-4014. PMID 26980160.
- Yoon, Hye-Jin; Cha, Bong Soo (2014-11-27). "Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease". World Journal of Hepatology. 6 (11): 800–811. doi:10.4254/wjh.v6.i11.800. ISSN 1948-5182. PMC 4243154. PMID 25429318.
- Chayanupatkul, Maneerat; Liangpunsakul, Suthat (2014-05-28). "Alcoholic hepatitis: a comprehensive review of pathogenesis and treatment". World Journal of Gastroenterology. 20 (20): 6279–6286. doi:10.3748/wjg.v20.i20.6279. ISSN 2219-2840. PMC 4033465. PMID 24876748.
- Basra, Sarpreet; Anand, Bhupinderjit S. (2011-05-27). "Definition, epidemiology and magnitude of alcoholic hepatitis". World Journal of Hepatology. 3 (5): 108–113. doi:10.4254/wjh.v3.i5.108. ISSN 1948-5182. PMC 3124876. PMID 21731902.
- Haga, Yuki; Kanda, Tatsuo; Sasaki, Reina; Nakamura, Masato; Nakamoto, Shingo; Yokosuka, Osamu (2015-12-14). "Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis". World Journal of Gastroenterology. 21 (46): 12989–12995. doi:10.3748/wjg.v21.i46.12989. ISSN 2219-2840. PMC 4674717. PMID 26675364.
- Grant, A; Neuberger J (1999). "Guidelines on the use of liver biopsy in clinical practice". Gut. 45 (Suppl 4): 1–11. doi:10.1136/gut.45.2008.iv1. PMC 1766696. PMID 10485854. Archived from the original on 2007-06-30.
The main cause of mortality after percutaneous liver biopsy is intraperitoneal haemorrhage as shown in a retrospective Italian study of 68 000 percutaneous liver biopsies in which all six patients who died did so from intraperitoneal haemorrhage. Three of these patients had had a laparotomy, and all had either cirrhosis or malignant disease, both of which are risk factors for bleeding.
- Green, RM; Flamm, S (October 2002). "AGA technical review on the evaluation of liver chemistry tests". Gastroenterology. 123 (4): 1367–84. doi:10.1053/gast.2002.36061. PMID 12360498.
- Pratt, DS; Kaplan, MM (Apr 27, 2000). "Evaluation of abnormal liver-enzyme results in asymptomatic patients". The New England Journal of Medicine. 342 (17): 1266–71. doi:10.1056/NEJM200004273421707. PMID 10781624.
- Ito, Katsuyoshi; Mitchell, Donald G. (2004). "Imaging Diagnosis of Cirrhosis and Chronic Hepatitis". Intervirology. 47 (3–5): 134–143. doi:10.1159/000078465. PMID 15383722.
- Allan, Richard; Thoirs, Kerry; Phillips, Maureen (2010-07-28). "Accuracy of ultrasound to identify chronic liver disease". World Journal of Gastroenterology. 16 (28): 3510–3520. doi:10.3748/wjg.v16.i28.3510. ISSN 1007-9327. PMC 2909550. PMID 20653059.
- Sahani, Dushyant V.; Kalva, Sanjeeva P. (2004-07-01). "Imaging the Liver". The Oncologist. 9 (4): 385–397. doi:10.1634/theoncologist.9-4-385. ISSN 1083-7159. PMID 15266092.
- Villar LM, Cruz HM, Barbosa JR, Bezerra CS, Portilho MM, Scalioni Lde P (2015). "Update on hepatitis B and C virus diagnosis". World Journal of Virology. 4 (4): 323–42. doi:10.5501/wjv.v4.i4.323. PMC 4641225. PMID 26568915.
- Neuman, Manuela G.; French, Samuel W.; French, Barbara A.; Seitz, Helmut K.; Cohen, Lawrence B.; Mueller, Sebastian; Osna, Natalia A.; Kharbanda, Kusum K.; Seth, Devanshi (2014-12-01). "Alcoholic and non-alcoholic steatohepatitis". Experimental and Molecular Pathology. 97 (3): 492–510. doi:10.1016/j.yexmp.2014.09.005. PMC 4696068. PMID 25217800.
- "Guidelines For Viral Hepatitis Surveillance And Case Management". www.cdc.gov. Archived from the original on 2016-03-10. Retrieved 2016-03-12.
- Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J. eds. (2013). Harrison's Manual of Medicine, 18e, Chapter 164: Chronic Hepatitis. New York, NY: McGraw-Hill.CS1 maint: multiple names: authors list (link) CS1 maint: extra text: authors list (link)
- "Hepatitis A Fact sheet N°328". WHO Media Centre. Archived from the original on February 21, 2014. Retrieved March 7, 2016.
- Voise, Nathan (Oct 2011). "Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention. A shot at hepatitis prevention". J Am Osteopath Assoc. 111 (10 Suppl 6): S13–6. PMID 22086888.
- "Adult Immunization Schedule by Vaccine and Age Group". www.CDC.gov. Archived from the original on March 5, 2016. Retrieved March 7, 2016.
- Longo, Dan L.; et al. (2013). Chapter 163: "Acute Hepatitis." Harrison's Manual of Medicine, 18e. New York, NY: McGraw-Hill.
- "Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection". www.cdc.gov. Archived from the original on 2016-03-06. Retrieved 2016-03-11.
- Chou, Roger; Dana, Tracy; Bougatsos, Christina; Blazina, Ian; Zakher, Bernadette; Khangura, Jessi (2014-01-01). Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Systematic Review to Update the 2004 U.S. Preventive Services Task Force Recommendation. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US). PMID 24921112.
- "Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection". World Health Organization. Archived from the original on 2016-02-20. Retrieved 2016-03-11.
- "ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists: Viral Hepatitis in Pregnancy". www.acog.org. Retrieved 2016-03-12.
- Esherick JS; Clark DS; Slater ED; et al. (2015). CURRENT Practice Guidelines in Primary Care 2015. New York, NY: McGraw-Hill.
- "Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease". MMWR. 47 (RR-19): 1–39. October 16, 1998. PMID 9790221. Archived from the original on March 24, 2016. Retrieved March 16, 2016.
- "Hepatitis C". World Health Organization. Archived from the original on 2016-01-31. Retrieved 2016-03-08.
- "Final Recommendation Statement: Hepatitis C: Screening - US Preventive Services Task Force". www.uspreventiveservicestaskforce.org. Archived from the original on 2016-03-21. Retrieved 2016-03-21.
- "Birth-18 Years and Catchup Immunization Schedules for Providers". www.CDC.gov. Archived from the original on March 6, 2016. Retrieved March 7, 2016.
- Centers for Disease Control (1999). "Update: recommendations to prevent hepatitis B virus transmission—United States. MMWR 1999". 48: 33–4. Archived from the original on May 14, 2016. Retrieved March 7, 2016. Cite journal requires
- "Hepatitis A And Hepatitis B Vaccine (Intramuscular Route)". Mayo Clinic. Retrieved 25 January 2018.
- "Hepatitis E". World Health Organization. Archived from the original on 2016-03-06. Retrieved 2016-03-09.
- "WHO | Hepatitis D". www.who.int. Archived from the original on 2016-03-08. Retrieved 2016-03-09.
- Zhang; et al. (March 5, 2015). "Long-Term Efficacy of a Hepatitis E Vaccine". NEJM. 372 (10): 914–22. doi:10.1056/NEJMoa1406011. PMID 25738667.
- "Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®） - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Archived from the original on 2016-03-09. Retrieved 2016-03-09.
- "Drinking Levels Defined | National Institute on Alcohol Abuse and Alcoholism (NIAAA)". www.niaaa.nih.gov. 14 September 2011. Archived from the original on 2016-03-23. Retrieved 2016-03-09.
- Franco, Elisabetta; Meleleo, Cristina; Serino, Laura; Sorbara, Debora; Zaratti, Laura (2012-03-27). "Hepatitis A: Epidemiology and prevention in developing countries". World Journal of Hepatology. 4 (3): 68–73. doi:10.4254/wjh.v4.i3.68. ISSN 1948-5182. PMC 3321492. PMID 22489258.
- "Pinkbook | Hepatitis B | Epidemiology of Vaccine Preventable Diseases | CDC". www.cdc.gov. Archived from the original on 2016-03-07. Retrieved 2016-03-09.
- Carroll, Karen (2015). "Chapter 35: Hepatitis Viruses". Medical Microbiology. New York: McGraw-Hill. ISBN 978-0071824989.
- "Commentary | U.S. 2013 Surveillance Data for Viral Hepatitis | Statistics & Surveillance | Division of Viral Hepatitis | CDC". www.cdc.gov. Archived from the original on 2016-03-05. Retrieved 2016-03-09.
- Wright NMJ, Millson CE, Tompkins CNE (2005). What is the evidence for the effectiveness of interventions to reduce hepatitis C infection and the associated morbidity? Copenhagen, WHO Regional Office for Europe (Health Evidence Network report; "Archived copy" (PDF). Archived (PDF) from the original on 2010-05-01. Retrieved 2016-03-09.CS1 maint: archived copy as title (link), accessed 9 Mar 2016).
- Basra, Sarpreet; Anand, Bhupinderjit S (2011-05-27). "Definition, epidemiology and magnitude of alcoholic hepatitis". World Journal of Hepatology. 3 (5): 108–113. doi:10.4254/wjh.v3.i5.108. ISSN 1948-5182. PMC 3124876. PMID 21731902.
- "The Epidemiology of Alcoholic Liver Disease". pubs.niaaa.nih.gov. Archived from the original on 2016-03-03. Retrieved 2016-03-09.
- Messori, Andrea; Badiani, Brigitta; Trippoli, Sabrina (2015-12-01). "Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures". Clinical Drug Investigation. 35 (12): 843–850. doi:10.1007/s40261-015-0338-y. ISSN 1179-1918. PMID 26446006.
- Thiagarajan, Prarthana; Ryder, Stephen D. (2015-12-01). "The hepatitis C revolution part 1: antiviral treatment options". Current Opinion in Infectious Diseases. 28 (6): 563–571. doi:10.1097/QCO.0000000000000205. ISSN 1473-6527. PMID 26524328.
- Gogela, Neliswa A.; Lin, Ming V.; Wisocky, Jessica L.; Chung, Raymond T. (2015-03-01). "Enhancing our understanding of current therapies for Hepatitis C virus (HCV)". Current HIV/AIDS Reports. 12 (1): 68–78. doi:10.1007/s11904-014-0243-7. ISSN 1548-3568. PMC 4373591. PMID 25761432.
- Abbas, Zaigham; Khan, Muhammad Arsalan; Salih, Mohammad; Jafri, Wasim (2011-12-07). "Interferon alpha for chronic hepatitis D". Cochrane Database of Systematic Reviews (12): CD006002. doi:10.1002/14651858.cd006002.pub2. PMC 6823236. PMID 22161394.
- "HEV FAQs for Health Professionals | Division of Viral Hepatitis | CDC". www.cdc.gov. Archived from the original on 2016-03-08. Retrieved 2016-03-17.
- Singh, Siddharth; Murad, Mohammad Hassan; Chandar, Apoorva K.; Bongiorno, Connie M.; Singal, Ashwani K.; Atkinson, Stephen R.; Thursz, Mark R.; Loomba, Rohit; Shah, Vijay H. (2015-10-01). "Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis". Gastroenterology. 149 (4): 958–970.e12. doi:10.1053/j.gastro.2015.06.006. ISSN 1528-0012. PMID 26091937.
- Thursz, Mark; Forrest, Ewan; Roderick, Paul; Day, Christopher; Austin, Andrew; O'Grady, John; Ryder, Stephen; Allison, Michael; Gleeson, Dermot (2015-12-01). "The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial". Health Technology Assessment (Winchester, England). 19 (102): 1–104. doi:10.3310/hta191020. ISSN 2046-4924. PMC 4781103. PMID 26691209.
- Rambaldi, Andrea; Jacobs, Bradly P; Gluud, Christian (2007-10-17). "Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases". Protocols (4): CD003620. doi:10.1002/14651858.cd003620.pub3. ISSN 1465-1858. PMID 17943794.
- Bartenschlager, ed. (2013). Hepatitis C Virus: From Molecular Virology to Antiviral Therapy. Springer.
- Khuroo, MS (1981). "Incidence and severity of viral hepatitis in pregnancy". Am J Med. 70 (2): A32. doi:10.1016/0002-9343(81)90796-8.
- Gill, RQ (2001). "Acute Liver Failure". J Clin Gastroenterol. 33 (3): 191–8. doi:10.1097/00004836-200109000-00005. PMID 11500606.
- Smedile, A; et al. (1981). "Infection with the delta agent in chronic HBsAg carriers". Gastroenterology. 81 (6): 992–7. doi:10.1016/S0016-5085(81)80003-0. PMID 7286594.
- Abbas, Zaigham; Ali, Syed Salman; Shazi, Lubna (2015-06-02). "Interferon alpha versus any other drug for chronic hepatitis D". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd011727.
- Thein, Hla-Hla; Yi, Qilong; Dore, Gregory J.; Krahn, Murray D. (2008-08-01). "Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression". Hepatology. 48 (2): 418–431. doi:10.1002/hep.22375. ISSN 1527-3350. PMID 18563841.
- Fattovich, G (1997). "Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients". Gastroenterology. 112 (2): 463–72. doi:10.1053/gast.1997.v112.pm9024300. PMID 9024300.
- "Hepatitis A Information | Division of Viral Hepatitis | CDC". www.cdc.gov. Archived from the original on 2016-03-04. Retrieved 2016-03-08.
- Aggarwal, Rakesh; Goel, Amit (2015). "Hepatitis A". Current Opinion in Infectious Diseases. 28 (5): 488–496. doi:10.1097/qco.0000000000000188. PMID 26203853.
- "WHO | Hepatitis A". www.who.int. Archived from the original on 2014-02-21. Retrieved 2016-03-08.
- "Hepatitis A Questions and Answers for Health Professionals | Division of Viral Hepatitis | CDC". www.cdc.gov. Archived from the original on 2016-03-06. Retrieved 2016-03-08.
- Rosen, Hugo R. (2011-06-23). "Clinical practice. Chronic hepatitis C infection". The New England Journal of Medicine. 364 (25): 2429–2438. doi:10.1056/NEJMcp1006613. ISSN 1533-4406. PMID 21696309.
- Edlin, Brian R.; Eckhardt, Benjamin J.; Shu, Marla A.; Holmberg, Scott D.; Swan, Tracy (2015-11-01). "Toward a more accurate estimate of the prevalence of hepatitis C in the United States". Hepatology. 62 (5): 1353–1363. doi:10.1002/hep.27978. ISSN 1527-3350. PMC 4751870. PMID 26171595.
- "HEV FAQs for Health Professionals | Division of Viral Hepatitis | CDC". www.cdc.gov. Archived from the original on 2016-03-08. Retrieved 2016-03-09.
- Singal, Ashwani K.; Kamath, Patrick S.; Gores, Gregory J.; Shah, Vijay H. (2014-04-01). "Alcoholic hepatitis: current challenges and future directions". Clinical Gastroenterology and Hepatology. 12 (4): 555–564, quiz e31–32. doi:10.1016/j.cgh.2013.06.013. ISSN 1542-7714. PMC 3883924. PMID 23811249.
- Shoreibah, Mohamed; Anand, Bhupinderjit S.; Singal, Ashwani K. (2014-09-14). "Alcoholic hepatitis and concomitant hepatitis C virus infection". World Journal of Gastroenterology. 20 (34): 11929–11934. doi:10.3748/wjg.v20.i34.11929. ISSN 2219-2840. PMC 4161778. PMID 25232227.
- Singal, Ashwani K.; Anand, Bhupinder S. (2007-09-01). "Mechanisms of synergy between alcohol and hepatitis C virus". Journal of Clinical Gastroenterology. 41 (8): 761–772. doi:10.1097/MCG.0b013e3180381584. ISSN 0192-0790. PMID 17700425.
- Wree, Alexander; Broderick, Lori; Canbay, Ali; Hoffman, Hal M.; Feldstein, Ariel E. (2013-11-01). "From NAFLD to NASH to cirrhosis-new insights into disease mechanisms". Nature Reviews. Gastroenterology & Hepatology. 10 (11): 627–636. doi:10.1038/nrgastro.2013.149. ISSN 1759-5053. PMID 23958599.
- Weiß, Johannes; Rau, Monika; Geier, Andreas (2014-06-27). "Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment". Deutsches Ärzteblatt International. 111 (26): 447–452. doi:10.3238/arztebl.2014.0447. ISSN 1866-0452. PMC 4101528. PMID 25019921.
- Michelotti, Gregory A.; Machado, Mariana V.; Diehl, Anna Mae (2013-11-01). "NAFLD, NASH and liver cancer". Nature Reviews. Gastroenterology & Hepatology. 10 (11): 656–665. doi:10.1038/nrgastro.2013.183. ISSN 1759-5053. PMID 24080776.
- Trepo, Christian (February 2014). "A brief history of hepatitis milestones". Liver International. 34 (Supplement s1): 29–37. doi:10.1111/liv.12409. PMID 24373076.
- Oon, GC (July 2012). "Viral hepatitis—the silent killer". Annals of the Academy of Medicine, Singapore. 41 (7): 279–80. PMID 22892603.
- Lee, Christine A.; Thomas, Howard C., eds. (1988). Classic papers in viral hepatitis. Foreword by Dame Sheila Sherlock. London, England: Science Press. ISBN 978-1-870026-10-9.
- Purcell, RH (April 1993). "The discovery of the hepatitis viruses". Gastroenterology. 104 (4): 955–63. doi:10.1016/0016-5085(93)90261-a. PMID 8385046.
- Bradley, WH (1946). "Homologous Serum Jaundice". Proceedings of the Royal Society of Medicine. 39 (10): 649–654. doi:10.1177/003591574603901012. PMC 2181926. PMID 19993376.
- Munson, Ronald (1996). Intervention and Reflection: Basic Issues in Medical Ethics. pp. 273–281.
- Beecher, Henry (1966). "Ethics and Clinical Research". The New England Journal of Medicine. 274 (24): 1354–1360. doi:10.1056/nejm196606162742405. PMID 5327352.; Reprinted in Beecher HK (2001). "Ethics and clinical research. 1966". Bull World Health Organ. 79 (4): 367–72. PMC 2566401. PMID 11368058.
- Purcell, RH (April 1993). "The discovery of the hepatitis viruses". Gastroenterology. 104 (4): 955–63. doi:10.1016/0016-5085(93)90261-a. PMID 8385046.
- Emanuel, Ezekiel (2008). The Oxford Textbook of Clinical Research Ethics. Oxford University Press. pp. 80–85.
- Odelberg, Wilhelm (1976). Les Prix Nobel.
- Alter, Harvey J. (2014-01-01). "The road not taken or how I learned to love the liver: A personal perspective on hepatitis history". Hepatology. 59 (1): 4–12. doi:10.1002/hep.26787. ISSN 1527-3350. PMID 24123147.
- Blumberg BS; Alter HJ (1965-02-15). "A "new" antigen in leukemia sera". JAMA. 191 (7): 541–546. doi:10.1001/jama.1965.03080070025007. ISSN 0098-7484. PMID 14239025.
- "The Nobel Prize in Physiology or Medicine 1976". NobelPrize.org. Retrieved 2019-10-07.
- Udompap, Prowpanga; Kim, Donghee; Kim, W. Ray (2015-11-01). "Current and Future Burden of Chronic Nonmalignant Liver Disease". Clinical Gastroenterology and Hepatology. 13 (12): 2031–2041. doi:10.1016/j.cgh.2015.08.015. ISSN 1542-7714. PMC 4618163. PMID 26291665.
- Lemoine, Maud; Eholié, Serge; Lacombe, Karine (2015). "Reducing the neglected burden of viral hepatitis in Africa: Strategies for a global approach". Journal of Hepatology. 62 (2): 469–476. doi:10.1016/j.jhep.2014.10.008. PMID 25457207.
- Koslap-Petraco, Mary Beth; Shub, Mitchell; Judelsohn, Richard (2008). "Hepatitis A: Disease Burden and Current Childhood Vaccination Strategies in the United States". Journal of Pediatric Health Care. 22 (1): 3–11. doi:10.1016/j.pedhc.2006.12.011. PMID 18174084.
- Previsani, Nicoletta; Lavanchy, Daniel (2000). "Hepatitis A" (PDF). World Health Organization Global Alert and Response. World Health Organization. Retrieved March 5, 2016.
- Anonychuk, Andrea M.; Tricco, Andrea C.; Bauch, Chris T.; Pham, Ba'; Gilca, Vladimir; Duval, Bernard; John-Baptiste, Ava; Woo, Gloria; Krahn, Murray (2008-01-01). "Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies". PharmacoEconomics. 26 (1): 17–32. doi:10.2165/00019053-200826010-00003. ISSN 1170-7690. PMID 18088156.
- Chan, Henry Lik-Yuen; Jia, Jidong (2011-01-01). "Chronic hepatitis B in Asia—new insights from the past decade". Journal of Gastroenterology and Hepatology. 26: 131–137. doi:10.1111/j.1440-1746.2010.06544.x. ISSN 1440-1746. PMID 21199524.
- Dan, Yock Young; Aung, Myat Oo; Lim, Seng Gee (2008-09-01). "The economics of treating chronic hepatitis B in Asia". Hepatology International. 2 (3): 284–295. doi:10.1007/s12072-008-9049-2. ISSN 1936-0533. PMC 2716880. PMID 19669256.
- Lavanchy, D. (2004-03-01). "Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures". Journal of Viral Hepatitis. 11 (2): 97–107. doi:10.1046/j.1365-2893.2003.00487.x. ISSN 1352-0504. PMID 14996343.
- Younossi, Z. M.; Kanwal, F.; Saab, S.; Brown, K. A.; El-Serag, H. B.; Kim, W. R.; Ahmed, A.; Kugelmas, M.; Gordon, S. C. (2014-03-01). "The impact of hepatitis C burden: an evidence-based approach". Alimentary Pharmacology & Therapeutics. 39 (5): 518–531. doi:10.1111/apt.12625. ISSN 1365-2036. PMID 24461160.
- Myers, Robert P.; Krajden, Mel; Bilodeau, Marc; Kaita, Kelly; Marotta, Paul; Peltekian, Kevork; Ramji, Alnoor; Estes, Chris; Razavi, Homie (2014-05-01). "Burden of disease and cost of chronic hepatitis C infection in Canada". Canadian Journal of Gastroenterology & Hepatology. 28 (5): 243–250. doi:10.1155/2014/317623. ISSN 2291-2797. PMC 4049256. PMID 24839620.
- Centers for Disease Control and Prevention (CDC) (2003-11-28). "Hepatitis A outbreak associated with green onions at a restaurant—Monaca, Pennsylvania, 2003". MMWR. Morbidity and Mortality Weekly Report. 52 (47): 1155–1157. ISSN 1545-861X. PMID 14647018.
- Polgreen, Lydia (November 16, 2003). "Community Is Reeling From Hepatitis Outbreak". New York Times. Archived from the original on March 22, 2016. Retrieved March 10, 2016.
- Jordan, Ashly E.; Perlman, David C.; Neurer, Joshua; Smith, Daniel J.; Des Jarlais, Don C.; Hagan, Holly (2016-01-28). "Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis". International Journal of STD & AIDS. 28 (2): 145–159. doi:10.1177/0956462416630910. ISSN 1758-1052. PMC 4965334. PMID 26826159.
- Platt, Lucy; Easterbrook, Philippa; Gower, Erin; McDonald, Bethan; Sabin, Keith; McGowan, Catherine; Yanny, Irini; Razavi, Homie; Vickerman, Peter (2016-02-24). "Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis" (PDF). The Lancet. Infectious Diseases. 16 (7): 797–808. doi:10.1016/S1473-3099(15)00485-5. ISSN 1474-4457. PMID 26922272.
- Cunningham, F. Gary; et al. (2013). "Hepatic, Biliary, and Pancreatic Disorders." Williams Obstetrics, Twenty-Fourth Edition. New York, NY: McGraw-Hill.
- Tassopoulos, NC; et al. (June 1987). "Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults". Gastroenterology. 92 (6): 1844–50. doi:10.1016/0016-5085(87)90614-7. PMID 3569758.
- "A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children, and Adolescents". www.cdc.gov. Archived from the original on 2016-03-24. Retrieved 2016-03-16.
- Terrault, Norah A.; Bzowej, Natalie H.; Chang, Kyong-Mi; Hwang, Jessica P.; Jonas, Maureen M.; Murad, M. Hassan (2016-01-01). "AASLD guidelines for treatment of chronic hepatitis B". Hepatology. 63 (1): 261–283. doi:10.1002/hep.28156. ISSN 1527-3350. PMC 5987259. PMID 26566064.
- Wang, Liming; Kourtis, Athena P.; Ellington, Sascha; Legardy-Williams, Jennifer; Bulterys, Marc (2013-12-01). "Safety of tenofovir during pregnancy for the mother and fetus: a systematic review". Clinical Infectious Diseases. 57 (12): 1773–1781. doi:10.1093/cid/cit601. ISSN 1537-6591. PMID 24046310.
- Shi, Zhongjie; Yang, Yuebo; Ma, Lin; Li, Xiaomao; Schreiber, Ann (2010-07-01). "Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis". Obstetrics and Gynecology. 116 (1): 147–159. doi:10.1097/AOG.0b013e3181e45951. ISSN 1873-233X. PMID 20567182.
- Benova, Lenka; Mohamoud, Yousra A.; Calvert, Clara; Abu-Raddad, Laith J. (2014-09-15). "Vertical transmission of hepatitis C virus: systematic review and meta-analysis". Clinical Infectious Diseases. 59 (6): 765–773. doi:10.1093/cid/ciu447. ISSN 1537-6591. PMC 4144266. PMID 24928290.
- Jin, H.; Zhao, Y.; Zhang, X.; Wang, B.; Liu, P. (2016-03-01). "Case-fatality risk of pregnant women with acute viral hepatitis type E: a systematic review and meta-analysis". Epidemiology & Infection. FirstView (10): 2098–2106. doi:10.1017/S0950268816000418. ISSN 1469-4409. PMID 26939626.